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Abstract
 
The pathogenesis of immunoglobulin A (IgA) nephropathy (IgAN), the most prevalent form of
glomerulonephritis worldwide, involves circulating macromolecular IgA1 complexes. How-
ever, the molecular mechanism(s) of the disease remain poorly understood. We report here the
presence of circulating soluble Fc
 
a
 
R (CD89)-IgA complexes in patients with IgAN. Soluble
CD89 was identified as a glycoprotein with a 24-kD backbone that corresponds to the ex-
pected size of CD89 extracellular domains. To demonstrate their pathogenic role, we gener-
ated transgenic (Tg) mice expressing human CD89 on macrophage/monocytes, as no CD89
homologue is found in mice. These mice spontaneously developed massive mesangial IgA dep-
osition, glomerular and interstitial macrophage infiltration, mesangial matrix expansion, hema-
turia, and mild proteinuria. The molecular mechanism was shown to involve soluble CD89 re-
leased after interaction with IgA. This release was independent of CD89 association with the
FcR
 
g
 
 chain. The disease was induced in recombination activating gene (RAG)2
 
2/2
 
 mice by
injection of serum from Tg mice, and in severe combined immunodeficiency (SCID)-Tg mice
by injection of patients’ IgA. Depletion of soluble CD89 from serum abolished this effect.
These results reveal the key role of soluble CD89 in the pathogenesis of IgAN and provide an
in vivo model that will be useful for developing new treatments.
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Introduction
 
IgA nephropathy (IgAN),
 
1
 
 or Berger’s disease, is character-
ized by hematuria and IgA deposits in the mesangium (1,
2). The disease is associated with mononuclear cell infiltra-
tion in the kidney, which correlates with glomerular dam-
age and interstitial tissue injury (3–5). Within 10–20 yr of
onset, about one third of patients develop renal failure. The
pathogenic mechanisms underlying IgAN are poorly un-
derstood. They include a galactose deficiency of the IgA1
hinge region (6, 7) and formation of immune complexes
(ICs) containing polymeric IgA1 molecules (8–10). The
role of IgA-ICs in the pathogenesis of IgAN is supported
by the recurrence of IgA deposits in renal grafts (11). Some
of the components of IgA-containing ICs have been iden-
tified, such as IgG, fibronectin, and collagen (2, 7, 12).
Studies in mice have shown that mesangial IgA deposition
depends on multiple elements generating the macromolec-
ular IgA-IC, such as the polymeric nature of IgA (13, 14)
and levels of uteroglobin, which control IgA–fibronectin
IC formation (15). However, it is noteworthy that not all
patients with IgAN have fibronectin–IgA complexes (16),
and most components responsible for IgA-IC deposition
remain poorly identified (17).
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Abbreviations used in this paper:
 
 ALC, alcoholic liver cirrhosis; AP, alka-
line phosphatase; BUN, blood urea nitrogen; FcR, receptor for Ig Fc
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immune complex; MCD, minimal change disease; MSA, mouse serum
albumin; NOD, nonobese diabetic; PEG, polyethylene glycol; RAG, re-
combination activating gene; Tg, transgenic; WT, wild-type. 
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Based on observations of patients with IgAN, we postu-
lated that the IgA Fc receptor, CD89, was strongly in-
volved in the pathogenic mechanism of the disease (18,
19). In healthy individuals, CD89 is constitutively ex-
pressed on human myeloid cells as 55–75-kD glycoproteins
that bind IgA polymers more than monomers (20–22). In
IgAN, we observed a marked decrease in monocyte CD89
expression (18). Despite low receptor numbers, increased
CD89 occupancy by IgA1 is found on monocytes of IgAN
patients and is linked to the severity of renal lesions such as
glomerulosclerosis and mesangial proliferation.
In this study, we first detected soluble CD89 complexed
with IgA in the serum of patients with IgAN, contrary to
patients with other IgA-related and -unrelated diseases. To
determine the role of soluble CD89 in the pathogenesis of
IgAN, we then generated CD89 transgenic (Tg) mice with
high level protein expression on monocyte/macrophages,
driven by the mouse CD11b promoter. We obtained direct
evidence that soluble CD89 is involved in IgA-IC forma-
tion, as CD89 Tg mice developed IgAN with macrophage
infiltration in damaged glomeruli. The heavy hematuria in
mice that received Tg serum or patients’ IgA suggests that
soluble CD89–IgA complexes are pathogenic and that the
nature of the IgA controls the formation of these com-
plexes.
 
Materials and Methods
 
Subjects. 
 
Serum was obtained from 30 patients with biopsy-
proven IgAN (23 males and 7 females), 30 healthy laboratory vol-
unteers (17 males and 13 females), 11 patients with minimal
change disease (MCD), 14 patients with rheumatoid arthritis, and
20 patients with alcoholic liver cirrhosis (ALC). Patients were se-
lected on the basis of no severe renal failure and no steroid treat-
ment. Some experiments used heparinized blood. The study was
approved by the Hôpital Necker Ethics Committee.
 
Constructs, Tg Mice, and Cell Lines. 
 
A construct encoding
human CD89 was obtained by inserting a 896-bp BamHI frag-
ment containing the human CD89 a.1 isoform gene (23) into the
BamHI site of the pB202–D736 construct containing the 1.7-kb
mouse CD11b promoter (provided by D. Tenen, Harvard Medi-
cal School, Boston, MA) (24). An electroeluted 4.8-kb DNA
XhoI-NotI fragment was microinjected into fertilized nonobese
diabetic (NOD) eggs and reimplanted into (NOD 
 
3
 
 C57BL/
6)F1 foster mothers as described elsewhere (25). Three offspring
were found to contain the human Fc
 
a
 
R cDNA by Southern blot
or by PCR of tail DNA using either a cDNA probe (provided by
C. Maliszewski, Immunex Corp., Seattle, WA; reference 22) or
transgene-specific primers 5
 
9
 
-GGGGAATTCGACGCAAA-
CAAGGCAGGGCGC-3
 
9
 
 and 5
 
9
 
-GGGGTCGACCTTGCA-
GACACTTGGTGTTCG-3
 
9
 
. The C57BL/6 background was
introduced into CD89 Tg mice of all three lines by more than
four consecutive crosses with C57BL/6 mice. The SCID muta-
tions were introduced into CD89-CD11b Tg mice (line 83) by
two consecutive crosses with SCID-NOD mice. Tg mice ho-
mozygous for the SCID defect were first selected by immunoflu-
orescence of blood lymphocytes and then confirmed by CD89
PCR typing of their progeny. We used heterozygous mice be-
cause they provide littermate controls. All mouse strains used in
this study were raised and housed in strictly controlled specific
 
pathogen-free conditions. Recombination activating gene (RAG)-
2
 
2/2
 
 mice, backcrossed nine times to C57BL/6, were obtained
from the Centre National de la Recherche Scientifique Central
Animal Facility. Rat basophilic cell lines (RBL-2H3) expressing
CD89 (wild-type [WT]), and a mutated version with Leu instead
of Arg at position 209 of the transmembrane region (R209L)
were used as described previously (26). CD89 R209L expression
was stable on the cell surface and was not associated with the FcR
 
g
 
 chain, as expected (26). Recombinant soluble CD89 was pro-
duced as described previously (27).
 
Antibodies. 
 
The murine IgG1 anti-Fc
 
a
 
R mAbs A3, A62,
and A77, recognizing epitopes on the extracellular domains of
Fc
 
a
 
R (28), were purified in our laboratory. F(ab
 
9
 
)
 
2
 
 fragments of
A3 and A77 mAbs were prepared by pepsin digestion (Sigma-
Aldrich) as described elsewhere (29). The murine IgM anti-CD89
mAb My43, which blocks IgA binding, was provided by L. Shen
(Dartmouth Medical School, Lebanon, NH; reference 30). To
generate anti-CD89 intracytoplasmic (Cy-
 
a
 
) region antibodies,
Cy-
 
a
 
 was PCR amplified and introduced into a glutathione
 
S
 
-transferase (GST) gene fusion vector (pGEX; Amersham Phar-
macia Biotech). GST-Cy-
 
a
 
 was produced and purified to immu-
nize rabbits (with help from U. Blank, Institut Pasteur). Purified
anti–Cy-
 
a
 
 antibodies were able to immunoprecipitate CD89
molecules from lysates of U937 cells (not shown). mAb A62,
mAb A77, and a polyclonal anti–Cy-
 
a
 
 antibody were coupled to
biotin. PE-conjugated A59 was purchased from BD PharMingen.
Goat anti–human IgA, and anti–human IgG coupled to alkaline
phosphatase (AP) were purchased from Southern Biotechnology
Associates, Inc. Biotinylated mouse anti–rat antibodies were pur-
chased from Jackson ImmunoResearch Laboratories. Mac-1 and
F4/80 hybridomas were provided by F. Lepault (Centre National
de la Recherche Scientifique, URA 1461, Paris, France). Human
dimeric monoclonal IgA1
 
k
 
 was obtained from a patient with my-
eloma (26). Mouse monoclonal dimeric IgA purified from ascites
of the IgA-C5 hybridoma was provided by A. Phalipon (Institut
Pasteur) (31). MOPC315 IgA was purchased from American
Type Culture Collection. Purified IgA was biotinylated as de-
scribed elsewhere (26).
 
Flow Cytometry. 
 
Cell suspensions (10
 
6
 
) from the peritoneal
cavity and heparinized blood were incubated with 2.4G2 and hu-
man IgG to block Fc
 
g
 
R. For two-color staining, cells were
stained with PE-conjugated A59 and with FITC-labeled mac-1
for 30 min at 4
 
8
 
C before red cell lysis with Becton Dickinson lysis
buffer. In some experiments cells were stained with biotinylated
mAb A77 (0.1 mg/ml) followed by streptavidin-PE as developing
reagent. Stained cells were analyzed on a FACSCalibur™ (Bec-
ton Dickinson) using CELLQuest™ software.
 
Cell Radiolabeling and Immunoprecipitation. 
 
Cell surface iodi-
nation with Na
 
125
 
I (1 mCi; Amersham Pharmacia Biotech) used
the lactoperoxidase method. For immunoprecipitation, cells
(10
 
7
 
/ml) were lysed for 30 min at 4
 
8
 
C in PBS containing 0.5%
NP-40 (Sigma-Aldrich), 0.02% sodium azide, 1% aprotinin, 1
mM diisopropylfluorophosphate, 5 mM iodoacetamide, and 1
mM PMSF. After centrifugation at 14,000 
 
g 
 
for 30 min to re-
move insoluble material, cleared lysates were immunodepleted of
Fc
 
g
 
R by using human IgG and mAb 2.4G2 precipitated with
A77 F(ab
 
9
 
)
 
2
 
 fragments coupled to Sepharose 4B as described pre-
viously (26). Bound materials were treated or untreated with
peptide 
 
N
 
-glycosidase F (Oxford GlycoSystems) and samples
were subsequently prepared for SDS-PAGE (32). For metabolic
labeling, blood monocytes (5 
 
3
 
 10
 
6
 
) were first starved for 1 h at
37
 
8
 
C in Met
 
2
 
/Cys
 
2 
 
RPMI medium, and then pulsed for 18 h in
2 ml of Met
 
2
 
/Cys
 
2
 
 RPMI containing 1 mCi of 
 
35
 
S-Met/Cys 
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Translabel (specific activity 1,175 Ci/mmol; ICN Biomedicals),
10% Met
 
2
 
/Cys
 
2
 
 FCS (Myoclone; GIBCO BRL), and 2 mM
glutamine. After washes, cells were chased in RPMI containing
10% FCS for 48 h. Cells were microfuged and 1.5 ml of superna-
tant was collected. The cell pellet was lysed in 0.5% NP-40 lysis
buffer as described above. Lysates and supernatants were immu-
noprecipitated as described above, and proteins were separated by
SDS-12% PAGE and revealed by autoradiography.
 
Solid-Phase ELISA for Soluble CD89 and IgA. 
 
To detect sol-
uble CD89, we used two mAbs directed against epitopes ex-
pressed on the extracellular domain and a polyclonal antibody di-
rected against CD89-Cy-
 
a
 
. 96-well plates (Dynex Technologies,
Inc.) were coated with F(ab
 
9
 
)
 
2
 
 fragments of mAb A3 (5 
 
m
 
g/ml),
blocked with PBS containing 1% BSA, and incubated overnight
at 4
 
8
 
C with test samples (1:2 to 1:20 dilutions in PBS containing
0.05% Tween 20). Recombinant soluble CD89 (27) and a U937
cell lysate were used as standard positive controls. After washes,
biotin-labeled anti-Fc
 
a
 
R antibodies (5 
 
m
 
g/ml) recognizing either
the extracellular domains (clone A62 or A77) or the cytoplasmic
tail (Cy-
 
a
 
) were added. In some experiments, biotin-labeled
anti-IgA or anti-IgG was used to detect sCD89–Ig complexes.
After 2 h of incubation at room temperature, the plates were
washed and incubated with streptavidin-AP (1:2,000 dilution).
The reaction was developed by adding the AP substrate, and ab-
sorbance was read at 405 nm. To determine circulating ICs con-
taining soluble CD89, serum samples were precipitated with
polyethylene glycol (PEG) 6000 (Merck-Clevenot) as described
elsewhere (10). Before analysis, each PEG precipitate was redis-
solved in 500 
 
m
 
l of 0.01 M phosphate buffer, pH 7.4, containing
0.5 M NaCl and 0.05% Tween 20. Levels of IC-containing
 
Fc
 
a
 
R were then estimated as described above. Patients’ results
are expressed in SD units (SDU) according to the formula: SDU 
 
5
 
(
 
X
 
t
 
 – 
 
X
 
n
 
)/SD
 
n
 
, where 
 
X
 
t
 
 is the mean value (absorbance) of each
test sample, 
 
X
 
n
 
 is the mean value of samples from 12 healthy
blood donors assayed simultaneously, and SD
 
n
 
 is the SD of the
mean value obtained for the panel of healthy donors as described
elsewhere (10). Mouse IgA was measured by coating plates with a
rat anti–mouse IgA mAb (clone R5-140; BD PharMingen) at 10
 
m
 
g/ml and developed by adding biotinylated goat anti–mouse
IgA (Southern Biotechnology Associates, Inc.) plus streptavidin-
AP. The standard curve was constructed with purified mouse IgA
(Sigma-Aldrich).
 
Morphologic Analyses. 
 
Kidney tissues were fixed in 3.6%
paraformaldehyde, dehydrated in graded alcohols, and embedded
in paraffin. Sections 2–3 
 
m
 
m thick were deparaffinized and rehy-
drated before staining with hematoxylin and eosin and periodic
acid-Schiff.
 
Immunohistochemistry. 
 
Frozen tissue sections 3-4 
 
m
 
m thick
were adhered to microscope slides (Superfrost Plus; VWR Scien-
tific), fixed in acetone (HPLC grade; Sigma-Aldrich) for 10 min
at 4
 
8
 
C, and then allowed to air dry for at least 1 h. Slides were
washed in PBS for 5–10 min, followed by the avidin/biotin
blocking steps. Slides were loaded with normal horse serum
(Vector Labs) for 30 min to block nonspecific sites. The primary
antibody (rat mAb) was incubated for 60 min in a humid cham-
ber (Vector Labs), and the biotinylated mouse anti–rat Ig (Jackson
ImmunoResearch Laboratories) was added and supplemented
with 2% normal mouse serum. The avidin/biotin-horseradish
peroxidase complex (ABC-HRP reagent; Vector Labs) was then
added, followed by 3,3
 
9
 
-diaminobenzidine tetrahydrochloride
Figure 1. Characterization of soluble CD89 in serum ICs of
patients with IgAN. (A) Soluble CD89 was detected in PEG
precipitates from patients with IgAN (n 5 30), but not in their
serum (except for one patient), by using a sandwich ELISA
with two anti-CD89 mAbs (A3 F[ab9]2/A77 as capture/devel-
oping antibodies). In contrast, no significant increase in soluble
CD89 was found in PEG precipitates from normal, healthy
controls (Co) and patients with rheumatoid arthritis (RA, n 5
14), MCD (n 5 11), and ALC (n 5 20). Results are expressed
in SD units as described in Materials and Methods. (B) Detec-
tion of IgA within CD891 PEG precipitates by ELISA using
A3 F(ab9)2 and anti–human IgA antibodies. No IgG was found
with anti-IgG antibodies. (C) Biochemical characterization of
soluble FcaR (CD89). Blood monocytes (107) from two
IgAN patients (Pat-1 and Pat-2) were pulsed for 18 h in 35S-
Met/Cys and chased for 48 h. Cells were spun and superna-
tants (SUP) were collected. Cell pellets were lysed and immu-
noprecipitated with either an irrelevant mouse IgG1k mAb
(lanes 1, 3, 5, and 7) or anti-CD89 A77 F(ab9)2 coupled to
beads (lanes 2, 4, 6, and 8). After immunoprecipitation, mate-
rials were treated or untreated with N-glycosidase F (N-gly) as
described elsewhere (reference 21). Materials were then sepa-
rated by SDS-12% PAGE. The arrows indicate the 24-kD
band of deglycosylated soluble CD89. 
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(DAB). Hematoxylin (1 min) and blueing steps were completed.
Slides were then water washed, dehydrated with ethanol, cleared
in xylene, and coverslipped.
 
Albuminuria and Blood Urea Nitrogen. 
 
96-well plates (Dynex)
were coated with mouse serum albumin (MSA, 3 
 
m
 
g/ml; Sigma-
Aldrich), blocked with 1% casein (Sigma-Aldrich) in PBS, and
incubated for 1 h at 37
 
8
 
C with urine samples (pure and 1:2 dilu-
tions) in PBS containing 1:5,000-diluted rabbit anti-MSA anti-
bodies (Cappel Laboratories). MSA was used as the standard con-
trol. After washes, HRP-labeled anti–rabbit antibodies (5 
 
m
 
g/ml;
Jackson ImmunoResearch Laboratories) were added followed
by 2,2
 
9
 
-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS).
Blood urea nitrogen (BUN) levels were determined using an
autoanalyzer (Hitachi 917; Boehringer) with commercially avail-
able kits.
 
Statistical Analyses. 
 
Differences between groups were deter-
mined by Student’s 
 
t
 
 test and the nonparametric Mann-Whitney
U test, as indicated. Results are presented as means 
 
6 
 
SEM.
 
Results
Identification of Soluble CD89–IgA Complexes in Circulating
ICs from Patients with IgAN.  High levels of soluble CD89
were detected in 40% (12/30) of PEG precipitates from
IgAN patients’ sera, whereas only one patient had increased
soluble CD89 in serum as free form using a sandwich
ELISA with two mAbs specific for CD89 extracellular do-
mains (Fig. 1 A). No significant increase in soluble CD89
was detected in PEG precipitates of serum from patients
with other IC diseases (e.g., rheumatoid arthritis), elevated
serum IgA (e.g., ALC), or another renal disease (e.g.,
MCD) (Fig. 1 A). To investigate whether soluble CD89
was complexed with IgA within the IC, we developed an
ELISA based on anti–CD89 F(ab9)2 mAb (clone A3) as
capture antibody and anti–human IgA as developing anti-
body. High levels of IgA were detected in ICs containing
soluble CD89 from IgAN patients (Fig. 1 B). In contrast,
no IgG was detected, indicating that the interaction of sol-
uble CD89 with IgA is isotype specific. To characterize the
soluble CD89, we cultured metabolically labeled blood
monocytes from two IgAN patients. After 48 h of culture,
heavily glycosylated CD89 molecules (50–70 kD) were
specifically immunoprecipitated from supernatants of both
patients’ samples by an anti-CD89 F(ab9)2 mAb (Fig. 1 C).
N-glycosidase F treatment of A77 F(ab9)2-reactive mole-
cules precipitated from supernatants gave rise to a 24-kD
protein core and a 33-kD band, whereas treatment of the
corresponding molecules from cell lysates resulted in the
expected 32-kD backbone only (Fig. 1 C, lanes 4 and 8).
To determine if the soluble CD89 found in PEG precipi-
tates from IgAN patients contained an intracytoplasmic tail
(Cy-a), we used an ELISA method based on mAb A3 and
anti–CD89-Cy-a polyclonal antibody as capture and/or
developing antibodies. No reactivity was observed, indicat-
ing that soluble CD89 lacks the cytoplasmic tail. In con-
Figure 2. Generation and charac-
terization of three lines of Tg mice
expressing human CD89. (A) Struc-
ture of the transgene consisting of a
4.8-kb insert carrying the cDNA en-
coding the human CD89 (huCD89)
and pB202/D736 construct contain-
ing the 1.7-kb mouse CD11b pro-
moter. (B) Expression of CD89 on
peritoneal macrophages of Tg mice,
detected by two-color FACS® stain-
ing with anti-CD89 (A59-PE) and
anti-CD11b (mac-1–FITC) mAbs.
(C) Biochemical nature of CD89 on
macrophages of Tg mice. Equal
numbers of cells (107) from CD89-
Tg (lines 83 and 96) and littermate
controls (Co) were iodinated, solu-
bilized and immunoprecipitated by
anti-CD89 A77 F(ab9)2 coupled to
beads. Half the resulting material was
treated with N-glycosidase F as de-
scribed elsewhere (reference 21) and
separated on SDS-10% PAGE. (D)
Comparative analysis of CD89 ex-
pression on peritoneal macrophages
from the three Tg lines and line 83
SCID mice using overlay histograms
of anti-CD89 mAb (A59-PE) stain-
ing. (E) IgA binding capacity of
peritoneal macrophages from SCID-
Tg mice (line 83, black bars). Bio-
tinylated human dimeric IgA1 (dIgA1), mouse dIgA (IgA-C5) (0.2 mg/ml), and monomeric sIgA (mIgA; MOPC315) were used. Hatched bars represent
inhibition of IgA binding by the anti-CD89 mAb My43 (percentage of inhibition is indicated at the top of the columns), calculated as described else-
where (reference 26), after correction for background obtained with non-Tg–SCID littermate controls (SCID, white bars).2003 Launay et al.
trast, high reactivity (.1.2 OD) was obtained with the
control CD89 (membrane form from U937 cell lysates;
data not shown).
Generation of Human FcaR (CD89) Tg Mice.  As no
CD89 homologue has been found in mice (33, 34), we ex-
amined whether expression of human CD89 on mouse
monocyte/macrophages would induce alterations in the
mouse immune system. We generated three Tg mouse
lines in the C57BL/6 and SCID backgrounds, designated
73, 83, and 96, using a construct containing human full-
length CD89 cDNA under the control of the mouse
CD11b promoter (24) that confers high level protein ex-
pression on monocyte/macrophages (Fig. 2 A). Macro-
phages isolated from the peritoneal cavity of C57BL/6-Tg
and SCID-Tg mice expressed CD89 (Fig. 2 B). Macro-
phage CD89 expression was stable in these mice from 6–24
wk of age (data not shown). CD89 was heavily glycosyl-
ated, yielding 32- and 36-kD bands after N-glycosydase F
treatment, as described on human myeloid cells (21) (Fig. 2
C). The level of transgene expression was z10-fold higher
on macrophages from line 83 than from the other two lines
(Fig. 2 D). We next analyzed the ability of CD89 to bind
purified human and mouse IgA, using macrophages from
SCID-Tg mice (line 83). Binding of dimeric human and
mouse IgA was specifically inhibited by the anti–CD89
mAb My43 (84 and 80%, respectively; Fig. 2 E). No spe-
cific binding of monomeric IgA was observed. These ex-
periments indicated that CD89 could bind dimeric but not
monomeric mouse IgA. This was confirmed by increased
endogenous IgA binding to blood monocytes of C57BL/6-
Tg mice, as shown with anti-IgA antibodies (data not
shown).
Spontaneous Mesangial IgA Deposition and Hematuria in
Mice Expressing CD89.  Kidneys from C57BL/6-Tg mice
showed massive mesangial IgA deposition at 24 wk of age
(Fig. 3). This was more intense in line 83 than in the two
other lines, and correlated with the level of transgene ex-
pression on peritoneal macrophages (Figs. 2 and 3). Marked
infiltration by mac-11 mononuclear cells was observed in
the intra- and periglomerular regions surrounding the
Bowman space, indicating the presence of macrophages in
and around damaged glomeruli (Fig. 3, bottom). Interstitial
macrophage infiltration was also present in these Tg mice
(Fig. 3, and data not shown). Mac-11 cells positively
stained with F4/80 mAb, a macrophage-specific marker,
ruling out the presence of neutrophils (not shown). Time
sequence experiments (in line 83) revealed that IgA depos-
its and infiltration by mac-11 cells were visible in CD89-
Tg mice older than 12 wk (Fig. 4 A). CD89-Tg mice had
significant spontaneous microscopic hematuria after 18 wk
Figure 3. Mesangial IgA deposits and macro-
phage infiltration in the kidneys of CD89-Tg mice
(C57BL/6) at 24 wk of age. IgA and CD11b im-
munohistochemical staining was performed with rat
anti–mouse IgA mAb and mac-1 mAb, respectively,
as indicated on the left. The CD89-Tg lines (73, 96,
and 83) are indicated on the right. Tg and their
non-Tg littermate controls are indicated at the top.2004 Soluble CD89 Mediates the Development of IgA Nephropathy
(Fig. 4 B) and significant albuminuria at 24 wk (Fig. 4 C).
Histological analyses showed focal and segmental lesions
with glomerular hypertrophy, mesangial matrix expansion
without cellular proliferation, congested glomerular capil-
lary, and moderate interstitial mononuclear cell infiltration
focally condensed around glomeruli in 24-wk-old Tg mice
(Fig. 4 D). BUN levels were slightly, but not significantly,
increased in 24-wk-old Tg mice (Fig. 4 E). However, these
mice had no increased mortality over a 1 yr period. No
CD89 staining was detected on kidney sections of CD89-
Tg mice using biotinylated anti-CD89 mAbs plus biotin/
avidin-HRP as a developing reagent (data not shown).
IgA-dependent Release of Soluble CD89 in Tg Mice.  To
determine the molecular mechanism involved in the
pathogenesis of IgAN in CD89-Tg mice, we first com-
pared CD89 expression on blood cells of C57BL/6-Tg and
SCID-Tg mice of line 83. CD89 expression was decreased
z10-fold on blood monocytes of CD89-Tg mice in the
C57BL/6 background compared with the same cell popu-
lation of SCID-Tg mice of line 83 (Fig. 5, A and B). Simi-
lar results were obtained with two other lines (73 and 96).
Dim CD89 expression was detected on neutrophils, except
for line 96, which has a subpopulation of neutrophils ex-
pressing CD89, and no expression was observed on lym-
phocytes of any mice of the three lines (data not shown).
Therefore, we analyzed CD89 expression as a function of
age. Blood cells from mice of line 83 were analyzed from 6
to 24 wk of age. As shown in Fig. 5 C, CD89 expression
fell after 12 wk of age as serum IgA levels increased. In
contrast, stable CD89 expression level was observed on
SCID-Tg mice (line 83) in which serum IgA was undetect-
able. As a control, CD11b antigen expression on mono-
cytes was similar in C57BL/6- and SCID-Tg mice (Fig. 5
D). To explain the decrease in CD89 expression on mono-
cytes, we sought for soluble CD89 in serum of Tg mice by
using a sandwich ELISA with either human IgA and an
anti-CD89 mAb or two anti-CD89 mAbs, as capture and
developing reagents. Significant reactivity of human IgA/
anti-CD89 mAb (clone A3) and of two mAbs (A3/A62)
towards soluble CD89 was obtained in serum from 24-wk-
old Tg mice (line 83) compared with littermate controls
(Fig. 5 E). Similar results were obtained with serum from
Tg mice of lines 73 and 96 (data not shown). Soluble
CD89 was only detected after 12 wk of age. No soluble
CD89 was detected in serum of SCID-Tg mice (line 83;
data not shown). To determine whether IgA could indeed
induce the release of soluble CD89, we used rat mast-cell
line (RBL-2H3) transfectants expressing either the full-
length CD89 (WT), or a receptor with a point mutation
(R to L at position 209) that is unable to associate with the
Figure 4. Time sequence of pathologic features in CD89 Tg mice of line 83. (A) IgA and CD11b stainings (indicated on the left) of three Tg mice at
different ages. Concomitant appearance of mesangial IgA deposits and periglomerular CD11b1 cells was seen in kidneys after 12 wk of age. (B) Signifi-
cant hematuria appeared in Tg mice after 18 wk of age (groups of 25 Tg mice, d, and 23 non-Tg littermates, s). (C) Mild albuminuria detected in urine
samples of 24-wk-old Tg mice. (D) Histologic kidney sections after periodic acid-Schiff (PAS) and hematoxylin and eosin (HE) staining from representa-
tive Tg mice and a non-Tg littermates (Lt) at different ages. Focal and segmental mesangial matrix expansion (white arrowhead) associated with con-
gested glomerular capillary (black arrowhead) and with glomerular hypertrophy was seen in 24-wk-old Tg mice but not in their littermate controls. (E)
BUN levels in Tg and non-Tg mice. *P , 0.001, and **P , 0.01.2005 Launay et al.
g chain (26). Culture of transfectants for 36 h with IgA in-
duced the release of soluble CD89 into supernatants of
both WT and R209L transfectants; this release was stronger
with dimeric IgA1 than monomeric IgA1 (Fig. 5 F). It was
specific for IgA, as it was not observed after culture with
IgG (Fig. 5 F). As R209L transfectants express only g-less
CD89, and as WT transfectants express both forms of
CD89 (26), our results indicate that soluble CD89 release
from cells is not dependent on the association of CD89
with the g chain.
Transfer of IgAN Disease into RAG-22/2 Mice by Serum
Soluble CD89 from CD89 Tg Mice. To test the patho-
genicity of soluble CD89 complexed to mouse IgA, we
injected serum from C57BL/6-Tg mice or littermate con-
trols (24-wk-old mice from line 83) into 8-wk-old RAG-
22/2 recipients. A single injection of serum (300 ml) of Tg
mice induced heavy, macroscopic hematuria for 24 h (Fig.
6 A) accompanied by mesangial IgA deposits and mac-11
cell infiltration in intra- and periglomerular regions (Fig. 6
B). No IgA deposition or cellular infiltration in glomerular
regions of RAG-22/2 mice receiving serum from littermate
controls was seen (Fig. 6 B). To demonstrate that soluble
CD89 mediates the transfer of IgAN disease, we pread-
sorbed serum from Tg mice with either an irrelevant con-
trol mAb (IgG1) or four anti-CD89 mAbs before injection
into RAG-22/2 recipients. A major decrease in hematuria,
IgA deposits, and mac-11 cell infiltration was observed
when serum was preadsorbed with anti-CD89 mAbs, indi-
cating the presence of nephritogenic soluble CD89 com-
plexes in the serum of Tg mice (Fig. 6 C).
Induction of IgAN Features in SCID–CD89 Tg Mice by In-
jection of Patient IgA.  In previous studies, we found that
increased interaction between patient IgA and CD89 re-
sults in CD89 downregulation on the monocyte surface
(18). To determine whether patient IgA can downregulate
CD89 expression in vivo and induce mesangial lesions and
clinical manifestations, we injected purified patient IgA and
normal IgA (100 mg) into 6-wk-old SCID-Tg mice (line
83) and monitored CD89 expression on blood monocytes.
As shown in Fig. 7 A, injection of patient IgA induced a
decrease of CD89 expression, with a maximal effect 2 h af-
ter injection. Patient IgA had a significantly stronger nega-
tive effect on CD89 expression than did normal serum IgA
(Fig. 7 B). Injection of patient IgA was followed by mac-
rophage infiltration in periglomerular areas 48 h later (Fig.
7 E), whereas no such cells were found in the kidney of
non-Tg–SCID mice injected with patient IgA (Fig. 7 D).
Weak mesangial human IgA deposition was also observed
(not shown). Interestingly, patient IgA induced heavy
and sustained macroscopic hematuria for a 72-h period,
whereas normal IgA only induced transient microscopic
hematuria that disappeared after 12 h (Fig. 7 C). Only tran-
Figure 5. Decreased expression of CD89 on
blood monocytes of CD89 Tg mice (line 83) is
associated with release of soluble CD89. (A)
Decreased CD89 expression on blood mono-
cytes from 6-wk-old CD89 C57BL/6-Tg mice
compared with SCID-Tg mice. Double stain-
ing was performed with anti-CD89 (A59) and
anti-CD11b (mac-1). (B) Comparative analysis
of CD89 expression on blood monocytes deter-
mined by overlay histograms. (C) Analysis of
CD89 expression and IgA levels as a function of
the age of C57BL/6-Tg (d) and SCID-Tg
mice (s). Every 3–6 wk, blood cells were
stained as stated above and IgA was measured in
serum (triangles). Intensity of expression was
evaluated by measuring fluorescence intensity
(FI) as described elsewhere (reference 21). (D)
No differences in CD11b expression were ob-
served between C57BL/6-Tg (j) and SCID-
Tg mice (h). (E) Detection of soluble CD89 in
serum of Tg mice. Serum from 24-wk-old
CD89 Tg mice and their littermate controls
(Co) was tested with a sandwich ELISA using
human IgA and/or anti-CD89 mAbs as indi-
cated. Results are expressed in arbitrary units as
described elsewhere (reference 25). (F) Release
of soluble CD89 was induced by IgA and was
independent of g chain association. RBL trans-
fectants expressing either WT or mutant
(R209L) CD89 were cultured with 0.25 mg/ml
biotinylated IgG or 0.25 mg/ml biotinylated
monomeric or dimeric human IgA1k. After
36 h, cells were spun and supernatants were
collected. Soluble CD89 was measured with an
ELISA using A3 F(ab9)2-coated plates and
streptavidin-HRP as developing reagent. Re-
sults are expressed in OD.2006 Soluble CD89 Mediates the Development of IgA Nephropathy
sient hematuria was obtained after injection of patient IgA
into non-Tg–SCID mice (not shown). No hematuria was
seen with normal IgA in non-Tg–SCID mice (not shown).
Discussion
Our data point to the existence of soluble CD89 in se-
rum of IgAN patients being most frequently found in this
disease in a complexed form with their ligand, the IgA.
Soluble FcR is a common feature of the FcR family (35).
This is one of the first identifications of a self component in
circulating macromolecular IgA complexes (2), and would
explain the marked decrease in CD89 expression on pa-
tients’ monocytes (18). Monocyte soluble CD89 was char-
acterized as 50–70-kD glycoproteins with a protein core of
24 kD, which differs from the 55–75-kD CD89 with a
32-kD CD89 backbone isolated from cell lysates. This is
consistent with the molecular weight of the previously re-
ported recombinant soluble CD89 (23,700), which corre-
sponds to receptor extracellular domains (27). Thus, the
24-kD backbone of soluble CD89 is probably a product of
proteolytic shedding. The loss of 60 amino acids (19 of
transmembrane, and 41 of intracytoplasmic domains) would
only decrease the Mr by 8 kD, and might not affect SDS-
PAGE mobility due to the heavy glycosylation of the ex-
tracellular domain. Shedding of soluble CD89 is also sup-
ported by experiments in which IgA, but not IgG, induces
its release from mast cell transfectants expressing either full-
length CD89 (that may or may not be associated with the g
chain) or a mutated version that cannot associate with the g
chain (26). This led us to the conclusion that soluble CD89
release is independent of the g chain association. The addi-
tional 33-kD band observed in supernatants could be ex-
plained by partial digestion by N-glycosidase F, as described
for the recombinant soluble CD89 produced by COS cells,
which gives rise to a major broad 25–30-kD band and a
smaller 23-kD protein core (27). However, we cannot rule
out from our experiments that the 33-kD band in the su-
pernatant corresponds to the product of an additional solu-
ble form of CD89 lacking only the transmembrane region
that would be secreted by monocytes. Transcripts encoding
for a soluble CD89 have been described in neutrophils and
eosinophils (36).
The results in CD89-Tg mice demonstrate that soluble
CD89 plays an essential role in the pathogenesis of IgAN.
Expression of CD89 on mouse monocyte/macrophages
was detrimental, mediating the development of IgAN
through the release of soluble CD89 after interaction with
mouse IgA. The mechanism underlying spontaneous IgAN
disease onset in CD89-Tg mice is probably linked to the
nature of mouse serum IgA, which is predominantly poly-
Figure 6. Features of IgAN induced by
cotransfer of serum from CD89 Tg donors
into RAG-22/2 recipients. 12 RAG-22/2
males (6 wk old) were injected intrave-
nously with 300 ml of pooled serum from 6
Tg donors or 6 littermate controls (line 83).
(A) Hematuria in RAG-22/2 mice receiving
serum from Tg (d, n 5 6) or littermate
mice (s, n 5 6). (B) RAG-22/2 kidneys
were stained with rat anti–mouse IgA mAb
(IgA) or with mac-1 mAb (CD11b), as indi-
cated.  (C) Decreased hematuria in RAG-
22/2 mice receiving serum from C57BL/6-
Tg donors after adsorption (four times) with
anti-CD89 mAb (A3, A59, A62, A77) cou-
pled to Sepharose beads (three in each
group) as indicated. As control, Tg serum
was adsorbed with an irrelevant IgG1 mAb
coupled to Sepharose beads.2007 Launay et al.
meric (70–80% of total serum IgA), contrary to the situa-
tion in humans (37), and also to the possible absence of a
CD89 homologue in mice (33, 34). We deduce that the
interaction between mouse polymeric IgA and the CD89
transgene product results in a release of pathogenic soluble
CD89–IgA complexes. This is supported by two observa-
tions: polymeric IgA induces a stronger release of soluble
CD89 than monomeric IgA in vitro, and the absence of
CD89 shedding from blood monocytes in SCID-Tg mice
in association with undetectable serum IgA levels is due to
their inherent immunodeficient status (Fig. 5). It is interest-
ing to note that increased levels of polymeric IgA observed
in the ddY mice induce IgA deposits without hematuria or
proteinuria (14). This reinforces the role of CD89 in IgAN
disease onset. Although CD89 was not directly detectable
in the mesangium, possibly owing to the poor sensitivity of
anti-CD89 mAbs in immunohistochemical staining, our
CD89 Tg mice are a valid model of spontaneous IgAN, as
they develop physical manifestations including microscopic
hematuria and mild albuminuria. Indeed, clinical IgAN on-
set in humans is usually defined by the presence of micro-
scopic hematuria associated with mild proteinuria (1, 17).
Regarding renal histology, the characteristic alterations in
CD89 Tg mice were progressive focal and segmental
mesangial matrix expansion with congested capillary and
glomerular hypertrophy. However, BUN levels were not
significantly altered. The absence of severe renal failure in
CD89-Tg mice suggests that progression of IgAN towards
renal failure requires other factors, such as inappropriate
protein expression by mesangial cells (e.g., megsin [38])
and/or T cell infiltration (5).
The pathogenic role of soluble CD89–IgA complexes
was demonstrated by transfer of the disease to RAG-22/2
mice injected with serum from Tg mice, but not with se-
rum from control mice, or serum from Tg mice adsorbed
with anti-CD89 mAbs (see Fig 6). As IgA induces soluble
CD89 release in vitro (Fig. 5 F), and to determine the role
of circulating soluble CD89 complexed with IgA, we per-
formed in vivo experiments in SCID-Tg mice using both
normal and patient IgA. It is important to note that CD89
downregulation was stronger with patient IgA than with
normal IgA, suggesting that the previously reported IgA
galactosylation deficiency and increased proportion of
polymeric IgA in IgAN patients play a role in CD89 shed-
ding (2). This is consistent with our previous data showing
that patient IgA binds more than normal IgA to monocytes
(18). The gross hematuria observed after injection of pa-
tient IgA in SCID-Tg but not SCID–non-Tg mice further
supports the pathogenic role of soluble CD89–IgA com-
plexes and provides a possible explanation for the linkage
between CD89 alterations and renal lesions in patients with
IgAN (18). The transient hematuria observed after injec-
Figure 7. Induction of gross hematuria and macrophage infiltration by injection of patient IgA into 6-wk-old SCID-Tg mice (line 83). IgA, purified
from a normal donor and from a patient with IgAN, was injected intravenously into SCID-Tg mice (n 5 12). Blood was collected at the times indicated
and double stained for CD89 (A59-PE) and CD11b. (A) Overlay histogram profiles of CD89 staining at the monocyte gate after injection of patient IgA.
(B) Comparative analyses of percentage variation in CD89 fluorescence intensity after injection of patient and normal IgA, estimated as described else-
where (reference 21). Open and filled symbols represent injections of normal and patient IgA, respectively; *P , 0.03. (C) Erythrocyte counts at the times
indicated. (D and E) Mac-1 and anti-CD11b kidney staining 48 h after injection of patient IgA into a SCID mouse and a SCID-Tg mouse, respectively.2008 Soluble CD89 Mediates the Development of IgA Nephropathy
tion of normal human IgA into SCID-Tg mice might be
explained by binding of monomeric IgA to CD89, which
can induce soluble CD89 release (Fig. 5 F). Indeed, tran-
sient monomeric IgA binding to CD89 has been demon-
strated previously (20, 39). Together, our data point to a
pathogenic role of patient IgA in the soluble CD89 release
and IgA complex formation in IgAN.
This study demonstrates that soluble CD89–IgA com-
plex deposition induces an influx of mononuclear cells,
mainly macrophages (mac-11F4-801), into the glomerular
and interstitial regions. This is consistent with observations
in IgAN patient kidney specimens (3, 4). Transfer experi-
ments demonstrated that macrophage influx was also de-
pendent on soluble CD89 complexed with IgA, as serum
from Tg mice adsorbed with anti-CD89 mAbs were not
able to transfer the disease. Mesangial deposition of soluble
CD89–IgA, which might depend on expression of other
IgA receptors by mesangial cells (40, 41), could lead to cell
activation and release of chemokines or other factors result-
ing in macrophage recruitment (42). Indeed, enhanced kid-
ney expression of monocyte chemotactic peptide 1 has
been observed in patients with IgAN (43). Moreover, mac-
rophage activation could trigger the release of proin-
flammatory cytokines (e.g., IL-6 and TNF-a) and/or che-
mokines that might induce mesangial matrix expansion,
hematuria, and proteinuria (44–47). Taken together, our
data point to a central role of soluble CD89–IgA complexes
in the pathogenesis of IgAN and provide evidence that the
nature (monomeric/polymeric and/or glycosylation status)
of the IgA controls the formation of these complexes.
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